← All trials
NCT06643078
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 11, 2023
- Primary completion
- Oct 31, 2025
- Completion date
- Oct 31, 2025
- First posted
- Oct 15, 2024
- Last posted
- Oct 15, 2024
- Enrollment
- 474
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Haisco PharmaceuticalLead sponsor
- Haisco PharmaceuticalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.